Matthew Osborne is our Vice President of Investor Relations and Corporate Communications. His healthcare career spans more than 20 years including 17 years of biotechnology Wall Street and investor relations/corporation communications experience. During this time, Matt advised companies in finance, raising more than $3 billion in equity and debt transactions, and provided strategic clinical, commercial and corporate communications across all stages of development, including during mergers and acquisitions. Matt’s industry experience includes global head of investor relations at Shire during its acquisition of Baxalta and Dyax, vice president of investor relations/corporate communications at Synageva BioPharma from its public inception through to its acquisition by Alexion, and investor relations at Vertex Pharmaceuticals during the transition of that company from a research to commercial stage and as part of an institutional investor highly-ranked investor relations team. On Wall Street, as a biotechnology sell-side analyst at Lazard and Leerink Partners, among others, Matt covered small to large cap biotechnology companies and analyzed several blockbuster drug launches across multiple therapeutic areas and launched several IPOs. Mr. Osborne received a Bachelor of Science in Biology from Syracuse University and a Master of Business Administration from the D’Amore-McKim School of Business at Northeastern University.

science